RVL Pharmaceuticals plc (RVLP) Misses Q4 EPS by 1c

RVL Pharmaceuticals plc (NASDAQ: RVLP) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $9.81 million versus the consensus estimate of $12.58 million.

For earnings history and earnings-related data on RVL Pharmaceuticals plc (RVLP) click here.

You May Also Be Interested In

• Meta to pay up to $16.68 billion in mass social media settlement
• CrowdStrike Holdings Inc. (CRWD) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY Guidance
• Okta, Inc. (OKTA) Tops Q2 EPS by 8c; offers guidance